Evidence map›Paper›PMID 34830979›Full record

ArticleCancers2021

Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma.

Kate I Glennon, Mahafarin Maralani, Narges Abdian, Antoine Paccard, Laura Montermini, Alice Jisoo Nam, Madeleine Arseneault, Alfredo Staffa, Pouria Jandaghi, Brian Meehan and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Kate I GlennonMcGill Genome Centre, McGill University, 740 Doctor Penfield Avenue, Montreal, QC H3A 0G1, Canada.
Mahafarin MaralaniMcGill Genome Centre, McGill University, 740 Doctor Penfield Avenue, Montreal, QC H3A 0G1, Canada.
Narges AbdianThe Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.ORCID 0000-0003-0858-1391
Antoine PaccardMcGill Genome Centre, McGill University, 740 Doctor Penfield Avenue, Montreal, QC H3A 0G1, Canada.ORCID 0000-0003-0738-5540
Laura MonterminiThe Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Alice Jisoo NamMcGill Genome Centre, McGill University, 740 Doctor Penfield Avenue, Montreal, QC H3A 0G1, Canada.
Madeleine ArseneaultMcGill Genome Centre, McGill University, 740 Doctor Penfield Avenue, Montreal, QC H3A 0G1, Canada.
Alfredo StaffaMcGill Genome Centre, McGill University, 740 Doctor Penfield Avenue, Montreal, QC H3A 0G1, Canada.
Pouria JandaghiMcGill Genome Centre, McGill University, 740 Doctor Penfield Avenue, Montreal, QC H3A 0G1, Canada.ORCID 0000-0003-1856-9396
Brian MeehanThe Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Fadi BrimoDepartment of Pathology, McGill University, Montreal, QC H3A 2B4, Canada.
Simon TanguayDivision of Urology, McGill University, Montreal, QC H4A 3J1, Canada.
Janusz RakThe Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Yasser RiazalhosseiniMcGill Genome Centre, McGill University, 740 Doctor Penfield Avenue, Montreal, QC H3A 0G1, Canada.
McGill Genome Centre · CAMcGill University Health Centre · CAMcGill University · CA

Funding

Canadian Cancer Society Research Institute Dr. Janusz RakKidney Foundation of Canada 2020KHRG-673291Kidney Foundation of Canada 2020KHRG-674624
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is known for its variable clinical behavior and outcome, including heterogeneity in developing relapse or metastasis. Recent data highlighted the potential of somatic mutations as promising biomarkers for risk stratification in RCC. Likewise, the analysis of circulating tumor DNA (ctDNA) for such informative somatic mutations (liquid biopsy) is considered an important advance for precision oncology in RCC, allowing to monitor molecular disease evolution in real time. However, our knowledge about the utility of ctDNA analysis in RCC is limited, in part due to the lack of RCC-appropriate assays for ctDNA analysis. Here, by interrogating different blood compartments in xenograft models, we identified plasma cell-free (cf) DNA and extracellular vesicles (ev) DNA enriched for RCC-associated ctDNA. Additionally, we developed sensitive targeted sequencing and bioinformatics workflows capable of detecting somatic mutations in RCC-relevant genes with allele frequencies ≥ 0.5%. Applying this assay to patient-matched tumor and liquid biopsies, we captured tumor mutations in cf- and ev-DNA fractions isolated from the blood, highlighting the potentials of both fractions for ctDNA analysis. Overall, our study presents an RCC-appropriate sequencing assay and workflow for ctDNA analysis and provides a proof of principle as to the feasibility of detecting tumor-specific mutations in liquid biopsy in RCC patients.

Indexed as

cfDNActDNAexosomesextracellular vesiclesliquid biopsyNGSrenal cell carcinoma

Identifiers

PMID34830979
PMCPMC8616270
OpenAlexW3216722440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.